# Exercise of options under employee stock option program and notification of insider trading - Egetis Therapeutics
Canonical URL: https://biopharmsignal.com/news/EGTX/exercise-of-options-under-employee-stock-option-program-and-notification-of-insi-e6812443
Ticker: EGTX
Company: Egetis
Source: Egetis
Published: 2026-07-09 15:46 EST
Original Source URL: https://www.egetis.com/mfn_news/
## Summary

Stockholm, May 13, 2026. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX) announces that on May 11, 2026, members of the Company’s executive management team exercised employee stock options granted under the employee stock option program (ESOP) 2022–2026. The final date for the exercise of options under ESOP 2022–2026 is June 15, […]

## Article Body
Stockholm, May 13, 2026. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX) announces that on May 11, 2026, members of the Company’s executive management team exercised employee stock options granted under the employee stock option program (ESOP) 2022–2026. The final date for the exercise of options under ESOP 2022–2026 is June 15, 2026. Any options not exercised by this date will lapse.

Following the exercise, Nicklas Westerholm (CEO), Yilmaz Mahshid (CFO), Christian Sonesson (VP Product Strategy & Development) and Karl Hård (VP Investor Relations & Business Development) sold shares solely to cover individual tax liabilities arising in connection with the shares received under ESOP 2022-2026.

Henrik Krook (VP Commercial Operations) has sold all of his newly allotted shares in order to finance part of a private residential purchase. Following the transaction, he continues to hold 459,593 shares in Egetis.
## Recent Company News
- 2026-07-09 15:46 EST — [Exercise of options under employee stock option program and notification of insider trading - Egetis Therapeutics](https://biopharmsignal.com/news/EGTX/exercise-of-options-under-employee-stock-option-program-and-notification-of-insi-e6812443) — Source: Egetis
- 2026-07-09 00:02 EST — [Egetis Therapeutics to Participate in Leading International Medical Conferences in 2026 - Egetis Therapeutics](https://biopharmsignal.com/news/EGTX/egetis-therapeutics-to-participate-in-leading-international-medical-conferences--5e606850) — Source: Egetis
- 2026-07-09 00:01 EST — [Egetis to present healthcare resource drivers and cost in MCT8 deficiency at ISPOR 2026 - Egetis Therapeutics](https://biopharmsignal.com/news/EGTX/egetis-to-present-healthcare-resource-drivers-and-cost-in-mct8-deficiency-at-isp-c2a98b15) — Source: Egetis
- 2026-07-09 00:01 EST — [Egetis Therapeutics Announces National Re-Airing of Behind the Mystery Episode on Lifetime Spotlighting MCT8 Deficiency - Egetis Therapeutics](https://biopharmsignal.com/news/EGTX/egetis-therapeutics-announces-national-re-airing-of-behind-the-mystery-episode-o-f519aa28) — Source: Egetis
- 2026-05-29 00:00 EST — [Change in the number of shares and votes in Egetis Therapeutics - Egetis Therapeutics](https://biopharmsignal.com/news/EGTX/change-in-the-number-of-shares-and-votes-in-egetis-therapeutics-egetis-therapeut-efcee0d2) — Source: Egetis
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)